Drug intelligence / Profile preview

crofelemer + loperamide

Development stage: Preclinical
Lead developer: Napo Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

A combination of two antidiarrheal medications with different mechanisms of action. Crofelemer is a botanical drug derived from the red latex of Croton lechleri that inhibits chloride channels in the intestine, reducing fluid secretion. Loperamide is a synthetic opioid receptor agonist that slows intestinal motility. This combination may provide enhanced efficacy in treating various types of diarrhea through complementary mechanisms.

Targets

MOR (Mu opioid receptor)CFTR (Cystic fibrosis transmembrane conductance regulator)CaCC (Calcium-activated chloride channel protein regulator 1)

Beyond the preview

Go deeper on crofelemer + loperamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on crofelemer + loperamide.

Explore the full profile